Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
21 studies found for:    intravenous immunoglobulin | alzheimer
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
Condition: Alzheimer´s Disease
Interventions: Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg;   Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg;   Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg;   Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
2 Completed
Has Results
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Placebo;   Biological: octagam 10%
3 Completed Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Intravenous Immunoglobulin
4 Recruiting A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: Albumin;   Biological: Immune globulin
5 Terminated
Has Results
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
Condition: Alzheimer´s Disease
Intervention: Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
6 Terminated
Has Results
Phase 3 IGIV, 10% in Alzheimer´s Disease
Condition: Alzheimer´s Disease
Interventions: Biological: Immune Globulin Intravenous (Human), 10% Solution;   Biological: Human albumin 0.25%
7 Active, not recruiting
Has Results
Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment
Condition: Mild Cognitive Impairment
Interventions: Drug: NewGam 10% IVIG;   Other: Placebo
8 Completed Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 8.5 mg/kg;   Drug: Placebo
9 Active, not recruiting Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb);   Drug: Placebo
10 Recruiting A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
Condition: Alzheimer Disease
Interventions: Drug: Crenezumab dose level 1;   Drug: Crenezumab dose level 2;   Drug: Crenezumb dose level 3;   Drug: Placebo
11 Completed Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BIIB037;   Other: Placebo
12 Completed A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: GSK933776;   Drug: Placebo to match GSK933776
13 Completed A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365;   Drug: Placebo
14 Recruiting A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
Condition: Alzheimer Disease
Interventions: Biological: LY3002813;   Drug: Placebo
15 Recruiting A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Placebo;   Drug: RO7105705
16 Active, not recruiting Continued Safety Monitoring of Solanezumab in Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
17 Active, not recruiting Single and Multiple Ascending Dose Study of BIIB037 in Japanese Participants With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BIIB037 (aducanumab);   Drug: Placebo
18 Completed
Has Results
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Condition: Alzheimer Disease
Intervention: Drug: bapineuzumab
19 Recruiting Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Condition: Dementia Alzheimer's Type
Interventions: Drug: Sargramostim GZ402664;   Drug: Placebo;   Drug: Florbetapir F18
20 Active, not recruiting Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Conditions: Alzheimers Disease;   Dementia;   Alzheimers Disease, Familial
Interventions: Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab)

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Indicates status has not been verified in more than two years